Golden State Equity Partners’s Cymabay Therapeutics CBAY Stock Holding History

Golden State Equity Partners’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$1.28M	Buy	54,289 +4,289	+9%	+$76.4K	0.31%	79
2023 Q3	$746K	Hold	50,000	–	–	0.21%	121
2023 Q2	$548K	Hold	50,000	–	–	0.15%	164
2023 Q1	$436K	Buy	+50,000	New	+$400K	0.24%	105
2022 Q1	$157K	Buy	50,600 +100	+0.2%	+$315	0.08%	183
2021 Q4	$171K	Buy	50,500 +17,650	+54%	+$67K	0.09%	164
2021 Q3	$120K	Buy	+32,850	New	+$129K	0.05%	226

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Golden State Equity Partners's CBAY Position: Q4 2023 in Review

Golden State Equity Partners increased its Cymabay Therapeutics (CBAY) stake by 8.6% in Q4 2023, buying an estimated $76.4K and bringing the position to 54,289 shares worth $1.28M. The position accounts for 0.31% of the portfolio, ranked #79.

Golden State Equity Partners first reported a position in CBAY in Q3 2021 and has held it in 7 quarters since. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

Golden State Equity Partners held 54,289 shares of Cymabay Therapeutics worth $1.28M as of Q4 2023.
Golden State Equity Partners bought 4,289 Cymabay Therapeutics shares in Q4 2023, an estimated $76.4K.
Cymabay Therapeutics made up 0.31% of Golden State Equity Partners's portfolio in Q4 2023, its #79 holding.
Golden State Equity Partners first reported a position in Cymabay Therapeutics in Q3 2021 and has held it in 7 quarters since.
200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Golden State Equity Partners's 13F filing for Q4 2023, filed 2 Feb 2024.